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OBJECTIVEdTo investigate the associations of metformin, serum vitamin B12, calcium sup-
plements, and cognitive impairment in patients with diabetes.
RESEARCH DESIGN ANDMETHODSdParticipants were recruited from the Primary
Research in Memory (PRIME) clinics study, the Australian Imaging, Biomarkers and Lifestyle
(AIBL) study of aging, and the Barwon region of southeastern Australia. Patients with Alzheimer
disease (AD) (n = 480) or mild cognitive impairment (n = 187) and those who were cognitively
intact (n = 687) were included; patients with stroke or with neurodegenerative diseases other
than AD were excluded. Subgroup analyses were performed for participants who had either type
2 diabetes (n = 104) or impaired glucose tolerance (n = 22).
RESULTSdParticipants with diabetes (n = 126) had worse cognitive performance than par-
ticipants who did not have diabetes (n = 1,228; adjusted odds ratio 1.51 [95% CI 1.03–2.21]).
Among participants with diabetes, worse cognitive performance was associated with metformin
use (2.23 [1.05–4.75]). After adjusting for age, sex, level of education, history of depression,
serum vitamin B12, and metformin use, participants with diabetes who were taking calcium
supplements had better cognitive performance (0.41 [0.19–0.92]).
CONCLUSIONSdMetformin use was associated with impaired cognitive performance. Vi-
tamin B12 and calcium supplements may alleviate metformin-induced vitamin B12 deﬁciency and
were associated with better cognitive outcomes. Prospective trials are warranted to assess the
beneﬁcial effects of vitamin B12 and calcium use on cognition in older people with diabetes who
are taking metformin.
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In 2010, more than 346 million peoplehad diabetes worldwide. Recent stud-ies from the U.K. (1) and Italy (2) re-
ported that the adult prevalence of
diabetes was approximately 4.2%. In the
U.S., the prevalence of diabetes in the
adult population may be as high as 14%
when undiagnosed cases are included (3).
The prevalence of diabetes may be higher
in some developing nations: in the devel-
oping region of southern China it was re-
ported to be 21.7% in 2010 (4). The
prevalence of diabetes is more than 20%
in some Paciﬁc Island nations, reaching
47% in 22- to 64-year-old American Sa-
moans (5).
In diabetes, hyperglycemia activates
the cellular signaling protein kinase C,
which induces production of the vaso-
constrictor protein endothelin-1. Excess
intracellular glucose is converted to sor-
bitol by the enzyme aldose reductase.
When intracellular levels of glucose are
high, this process exhausts the energy
substrate NADPH, resulting in oxidative
stress. High intracellular sorbitol levels
cause osmotic stress and cell death. These
biochemical changes in hyperglycemia
are a proposed mechanism for macro-
vascular and microvascular complica-
tions and neuropathy (6–8). Diabetes
is associated with a faster rate of cogni-
tive decline in those with mild cognitive
impairment (MCI) (9) and an increased
risk for developing Alzheimer disease
(AD) (10).
Approximately 90% of patients with
diabetes have type 2 diabetes (1). The bi-
guanide metformin is a ﬁrst-line treat-
ment for type 2 diabetes, increasing
glucose uptake in muscle while reducing
liver gluconeogenesis (the synthesis of
glucose from amino acids). These effects
are mediated by activation of the cellular
signaling protein AMP–activated protein
kinase (11).
Metformin ﬁrst became available in
the U.K. in 1958 and entered the Cana-
dian market in 1971, but it has been
available in the U.S. only since 1995. In a
survey of 65,000 U.S. war veterans (12),
metformin use among those with diabetes
increased from 29% in 2000 to 63% in
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2005. Among 242 Australian veterans
who had diabetes, metformin was used
by 75% in 2005 but decreased to 57%
in 2009 (13).
The rate of vitamin B12 deﬁciency
among patients who are takingmetformin
is reported to approach 30% (14–16).
A drug interaction between metformin
and the cubilin receptor inhibits the uptake
of vitamin B12 from the distal ileum, low-
ering serum vitamin B12 levels. In a long-
term, randomized, placebo-controlled
trial, metformin therapy in type 2 diabetes
was associated with a 19% reduction in
serum vitamin B12 concentrations com-
pared with placebo (17). In a case-control
study, Wile and Toth (18) reported that
metformin use was associated with re-
duced vitamin B12 levels and more severe
peripheral neuropathy in patients with
diabetes.
In a prospective trial, calcium supple-
ments were reported to reverse the drug
interaction that causes vitamin B12 deﬁ-
ciency induced by metformin (19). The
clinical signiﬁcance of alleviating metformin-
induced vitamin B12 malabsorption by
calcium supplementation has not been
previously investigated. By correcting vi-
tamin B12 levels in patients with diabetes
who usemetformin, calcium supplements
may help to preserve cognitive function. In
addition, neuronal signaling in memory
and learning involves a calcium-mediated
process, so calcium supplementation may
also have a direct effect on the brain. Cal-
cium dysregulation is the subject of one
proposed theory for age-related cognitive
changes and AD (20). The risks and po-
tential beneﬁts of calcium supplementa-
tion on cognition and for alleviating
vitamin B12 malabsorption merit further
investigation.
The amyloid plaques seen in the
brains of patients with AD are formed by
aggregation of Ab peptides. In cell cul-
tures, Chen and colleagues (21) reported
that activation of AMP–activated protein
kinase by metformin increased the ex-
pression of b-secretase, an enzyme that
increases the formation of Ab peptides.
One recent case-control study that in-
cluded 14,172 participants 65 years of
age or older reported that taking metfor-
min over the long term increased the risk
of AD (odds ratio [OR] 1.71 [95% CI
1.12–2.60]) (22).
Recent studies of murine models of
diabetes indicate that metformin may
attenuate irregularities in phosphoryla-
tion of tau proteins (23) or may facilitate
neuroneogenesis (24) and so may be of
beneﬁt to those with AD. In 25,393 pa-
tients older than 50 years with type 2 di-
abetes, metformin was reported to reduce
the risk of dementia by 24% (hazard ratio
0.76 [95% CI 0.58–0.98]) (25). The pur-
pose of our study was to investigate the
associations of metformin, serum vitamin
B12 levels, and cognition in a sample of
patients with diabetes.
RESEARCH DESIGN AND
METHODS
Participants and settings
Participants were recruited from two pro-
spective studies: the Prospective Research
in Memory (PRIME) clinics study and the
Australian Imaging, Biomarkers and Life-
style (AIBL) study of aging. Only data and
biochemical measurements pertaining to
baseline visits were included in this anal-
ysis. The PRIME study recruited 970
participants from 9 sites in Australia,
including 3 each in Victoria and New
South Wales and 1 each in Queensland,
Western Australia, and South Australia.
The AIBL study of aging recruited 1,112
participants in Victoria (60%) and West-
ern Australia (40%). The study cohorts
and methods of the PRIME and AIBL
studies are described elsewhere (26,27).
A further 862 participants who re-
sided in the Barwon region of southeast-
ern Australia between 2001 and 2011 also
were recruited through the Cognitive,
Dementia and Memory Services clinic at
the McKellar Centre, a rehabilitation and
aged-care facility. Patients with AD who
were seen at a geriatrician’s private prac-
tice during the same period also were re-
cruited (n = 935).
Study design
Participants in the PRIME study were
recruited during routine patient care.
AIBL participants volunteered after an
advertisement on television in late 2006.
The Mini-Mental State Examination
(MMSE) was used to assess cognitive
ability. Subjects were assessed at sched-
uled visits during the PRIME and AIBL
studies or ad hoc during routine patient
care. All participants with serum vitamin
B12 measurements taken within 6 months
of cognitive assessment were included.
Participants without serum measure-
ments taken within 6 months of cognitive
assessment (n = 1,015) were excluded.
The data from records pertaining to
subjects who were recruited from more
than one source (n = 566) were merged.
Of the remaining participants, there were
121 with stroke and 566 with diagnoses
other than AD, such as frontotemporal
dementia, Parkinson disease, dementia
with Lewy bodies, or mixed dementias.
Participants with other neurodegenera-
tive diseases were excluded to limit con-
founders. A further 291 participants were
excluded because they had incomplete
medical histories; information that was
missing included dates of birth, medica-
tion use, and comorbid conditions.
A subgroup analysis was performed
with participants who had diabetes (n =
104) or impaired glucose tolerance (n =
22). Patients with type 1 diabetes were not
speciﬁcally excluded, but there were
none with serum vitamin B12 measure-
ments taken within 6 months of cognitive
assessment.
Ethical approval
Institutional review was performed at
each study host site. Reviewing commit-
tees included the Barwon Health Human
Research Ethics Committee (HREC)
(Victoria), Austin Health HREC (Victoria),
St. Vincent’s Hospital Governance Review
Unit (Victoria), Hunter New England
HREC (New South Wales), Northern Hos-
pital Network HREC (New South Wales),
Northern Sydney Central Coast HREC
(New South Wales), Metro North Health
Service District HREC (Queensland),
South Metropolitan Area Health Service
HREC (Western Australia), and TheQueen
Elizabeth Hospital Ethics of Human Re-
search Committee (South Australia).
Statistical analyses
An ordinal logistic regression model was
formed with categories of cognitive per-
formance as the response variable and
diabetes as a predictor. Categories were
ordered by cognitive performance, in-
cluding “most impaired” (MMSE ,18;
n = 137), “mildly impaired” (MMSE 18–
23; n = 240), “minimally impaired”
(MMSE 24–27; n = 295), and “not im-
paired” (MMSE 28–30; n = 682). The
model was adjusted for age, sex, level of
education, and depression because these
factors were previously reported to affect
MMSE testing (28,29).
A subgroup analysis of only patients
with diabetes was then performed. The
response variable was cognitive perfor-
mance. Categories were “most impaired”
(MMSE ,18; n = 39), “mildly impaired”
(MMSE 18–23; n = 40), “minimally im-
paired” (MMSE 24–27; n = 32), and “not
impaired” (MMSE 28–30; n = 15). The
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effect of metformin on the cognitive per-
formance of patients with diabetes was in-
vestigated in this model, which then was
adjusted for serum vitamin B12 measure-
ments and use of calcium supplements to
investigate any possible interactions.
There was insufﬁcient information on
use of other antidiabetic drugs, the dura-
tion of metformin use, and markers for
socioeconomic status, diet, or exercise to
investigate these variables.
RESULTSdThere were 1,354 partici-
pants included in this analysis (Fig. 1).
Participants were 51–99 years old (mean
age6 SD 73.86 8.3 years); females out-
numbered males (59.5 vs. 40.5%). Just
more than half of the participants
(50.4%) scored 28–30 on the MMSE
and so were considered not impaired;
21.8% were minimally impaired (MMSE
24–27), 17.7% were mildly impaired
(MMSE 18–23), and 10.1% scored less
than 18 on the MMSE (most impaired).
Participants with diabetes were mar-
ginally older than participants without
diabetes (75.5 vs. 73.6 years; P = 0.013).
The number of males was proportionally
larger among participants with diabetes
(46.8 vs. 39.9%), but this difference was
not statistically signiﬁcant. Prevalence of
depression was similar between partici-
pants with diabetes and those without
diabetes (31.7 vs. 27.3%; P = 1.000).
The proportion of participants with a ter-
tiary level of education was higher among
participants without diabetes than partic-
ipants with diabetes (39.3 vs. 22.2%; P,
0.001). The number of participants who
scored below 28 on the MMSE was pro-
portionally higher among participants
with diabetes than those without diabetes
(69.0 vs. 47.6%; P = 1.000).
After adjusting for age, sex, educa-
tion, and depression, participants with
type 2 diabetes had worse cognitive perfor-
mance than participants without diabetes
(adjusted OR 1.51 [95% CI 1.03–2.21]).
Cognitive performance was better in youn-
ger participants, those without depression,
and those with a higher level of education.
The adjusted ORs for each predictor are
shown in Table 1.
Among participants with diabetes,
cognitive performance was worse in pa-
tients who were taking metformin (ad-
justed OR 2.23 [95% CI 1.05–4.75]).
MMSE scores were lower in participants
with diabetes who used metformin (mean
score 6 SD 22.8 6 5.5) than in those
who did not use metformin (24.7 6
4.4). Participants with diabetes who had
vitamin B12 levels ,250 rmol/L also
had worse cognitive performance (2.29
[1.12–4.66]). MMSE scores were lower
among those with serum vitamin B12
,250 rmol/L (22.9 6 4.7) than those
with higher levels (25.0 6 4.7).
Each 1-year increase in age was asso-
ciated with an 8% increased risk of im-
paired cognitive performance (OR 1.08
[95% CI 1.03–1.13]). A secondary or
Figure 1dRecruitment, inclusion, and exclusion.
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tertiary level of education was the strongest
predictor of better cognitive performance
in patients with diabetes. The adjusted
ORs for each variable are shown in Table 2.
CONCLUSIONSdIn our series, pa-
tients with diabetes who were taking met-
formin had worse cognitive performance
than participants who were not taking
metformin. Our observations agree with
those previously reported by Imfeld and
colleagues (22), in particular that patients
who are taking metformin may be at an
increased risk for cognitive impairment.
This associationwasweakened after adjust-
ing for serum vitamin B12 levels; thus any
effect metformin has on cognitive perfor-
mance may be at least partially mediated
by altering serum vitamin B12 levels.
Alternatively, patients who are pre-
scribedmetforminmay haveworse glycemic
control or diabetes-related complica-
tions than patients with diabetes who
are not prescribed metformin, so there
remains the potential for confounding,
despite restricting the analysis to only
patients with diabetes. However, be-
cause metformin is a ﬁrst-line pharma-
cotherapy for the treatment of type 2
diabetes, this would seem unlikely (30).
There was insufﬁcient information
regarding the duration of metformin use,
the severity of diabetes (e.g., HbA1c levels),
duration of diabetes, or use of other anti-
diabetic drugs to enable us to investigate
these effects in our study, particularly be-
cause these ﬁndings were based on a small
sample. We recommend a larger study to
examine the effect of dose and duration of
metformin use, and the effects of other an-
tidiabetic agents using a battery of cognitive
assessments and following participants
over a number of years.
Calcium supplements have previously
been reported to reverse vitamin B12 deﬁ-
ciency induced bymetformin. In this study,
patients with diabetes who used calcium
supplements were less likely to be cogni-
tively impaired. However, calcium supple-
ments have been reported to be associated
with an increased risk for myocardial in-
farction in postmenopausal women and
in patients with chronic kidney disease
(31–34). In contrast, a recent meta-analysis
indicates that supplementation with both
vitamin D and calcium is associated
with a reduction in mortality compared
with vitamin D supplementation alone
(35). Because this population already has
increased cardiovascular risk (36), the
safety of calcium supplementation in pa-
tients with diabetes treated withmetformin
would need to be established before such
interventions could be recommended.
Patients with diabetes are at an in-
creased risk for AD (10). In diabetes, amy-
lin aggregation destroys the b-cells of the
pancreas (37). By the same mechanism, a
protein misfolding disorder may be re-
lated to aggregation of amyloid plaques.
Metformin is a widely prescribed ﬁrst-line
monotherapy for type 2 diabetes but is
associated with vitamin B12 deﬁciency
and peripheral neuropathy. A case-control
study of more than 14,000 patients re-
ported that long-term metformin use
was associated with an increased risk
for AD in those$65 years old (22). Met-
formin at pharmacological doses was
reported to increase the expression of
b-secretase in cell culture; this may be a
possible disease mechanism (21). Alterna-
tively, metformin also impairs absorption
of vitamin B12 via a drug interaction that
occurs at the distal ileum. Low serum vi-
tamin B12 levels are associated with AD
and other neurodegenerative diseases
(38).
Cognitive performance of patients
with diabetes was measured using the
MMSE. The MMSEmay be inadequate for
detecting differences between higher
functioning adults (39). The MMSE is
sensitive to age, depression, and level of
education, so all models were adjusted for
these factors. Most of our subjects were
Table 1dCognitive performance in 1,354 participants who had AD or MCI or were cognitively intact
Categories, by predictor*
Model not adjusted for serum
vitamin B12 levels
Model adjusted for serum
vitamin B12 levels†
OR 95% CI P value OR 95% CI P value
Variable
Diabetes
Type 2 diabetes (n = 104) 1.51 1.03–2.21 0.033 1.49 1.02–2.19 0.039
Impaired glucose tolerance (n = 22)‡ 0.79 0.34–1.85 0.584 0.81 0.34–1.90 0.624
No diabetes (n = 1,228) d d d d d d
Model adjusters
Age (n = 1,354) 1.11 1.09–1.12 ,0.001 1.10 1.09–1.12 ,0.001
Sex
Male (n = 549) 0.88 0.70–1.10 0.257 0.86 0.69–1.08 0.186
Female (n = 805) d d d d d d
Depression
Yes (n = 375) 1.61 1.27–2.04 ,0.001 1.66 1.30–2.10 ,0.001
No (n = 979) d d d d d d
Level of educationx
Tertiary (n = 510) 0.12 0.08–0.17 ,0.001 0.12 0.08–0.17 ,0.001
Secondary (n = 674) 0.36 0.26–0.49 ,0.001 0.36 0.26–0.50 ,0.001
Primary (n = 170) d d d d d d
All models were adjusted for age, sex, reported history of depression, and level of education. Values obtained in themodel that also was adjusted for serum vitamin B12
levels are italicized. *Reference levels for categories were female sex, no reported history of depression, and having attained a primary level of education only (up to 6
years of schooling). †Serum vitamin B12 status was deﬁned as low (serum levels,250 rmol/L) or normal (serum levels.250 rmol/L). The reference level for serum
vitamin B12 status was normal. ‡Impaired glucose tolerance was by self-report or review of patient’s medical history. xCategories for level of education were tertiary
(.13 years of schooling), secondary (6–13 years of schooling), and primary (,6 years of schooling).
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assessed during routine clinical care by clini-
cians who use the MMSE as part of their
standard assessment. In Australia, docu-
mentation of cognitive impairment using
an MMSE score and improvement while re-
ceiving therapy is required to obtain subsi-
dized antidementia therapies (40). More
comprehensive assessment tools may be
preferable for use in future investigations
of cognitive impairment in at-risk popula-
tions such as those we have studied.
Increased monitoring of cognitive abil-
ity in patients with diabetes who use met-
formin is warranted, particularly among
older adults (aged older than 50 years).
Vitamin B12 supplements are inexpensive
and may improve the cognitive outcomes
of patients with diabetes. Adequately pow-
ered, prospective, controlled trials are war-
ranted to investigate further the association
between diabetes, cognitive decline, and
the effect of metformin therapy, as well as
the possible amelioration using vitamin B12
and/or calcium supplementation.
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